Cargando…
Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
RATIONALE: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for n...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287964/ https://www.ncbi.nlm.nih.gov/pubmed/28121940 http://dx.doi.org/10.1097/MD.0000000000005951 |
_version_ | 1782504248703975424 |
---|---|
author | Sarfaty, Michal Moore, Assaf Dudnik, Elizabeth Peled, Nir |
author_facet | Sarfaty, Michal Moore, Assaf Dudnik, Elizabeth Peled, Nir |
author_sort | Sarfaty, Michal |
collection | PubMed |
description | RATIONALE: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for nonsmall cell lung cancer (NSCLC) as a second-line therapy. PATIENT CONCERNS AND DIAGNOSIS: We present a patient with squamous NSCLC, suffering from multiple bone and subcutaneous metastases. INTERVENTIONS: The patient was treated with nivolumab. OUTCOMES: A subcutaneous lesion in her upper back grew substantially after the first cycle of nivolumab, and later regressed, with marked improvement in all cancer sites. LESSONS: Such pseudoprogression may serve to predict subsequent clinical response. |
format | Online Article Text |
id | pubmed-5287964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-52879642017-02-08 Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report Sarfaty, Michal Moore, Assaf Dudnik, Elizabeth Peled, Nir Medicine (Baltimore) 5700 RATIONALE: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for nonsmall cell lung cancer (NSCLC) as a second-line therapy. PATIENT CONCERNS AND DIAGNOSIS: We present a patient with squamous NSCLC, suffering from multiple bone and subcutaneous metastases. INTERVENTIONS: The patient was treated with nivolumab. OUTCOMES: A subcutaneous lesion in her upper back grew substantially after the first cycle of nivolumab, and later regressed, with marked improvement in all cancer sites. LESSONS: Such pseudoprogression may serve to predict subsequent clinical response. 2017-01-27 /pmc/articles/PMC5287964/ /pubmed/28121940 http://dx.doi.org/10.1097/MD.0000000000005951 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-sa/4.0 This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0 |
spellingShingle | 5700 Sarfaty, Michal Moore, Assaf Dudnik, Elizabeth Peled, Nir Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report |
title | Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report |
title_full | Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report |
title_fullStr | Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report |
title_full_unstemmed | Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report |
title_short | Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report |
title_sort | not only for melanoma. subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: a case report |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287964/ https://www.ncbi.nlm.nih.gov/pubmed/28121940 http://dx.doi.org/10.1097/MD.0000000000005951 |
work_keys_str_mv | AT sarfatymichal notonlyformelanomasubcutaneouspseudoprogressioninlungsquamouscellcarcinomatreatedwithnivolumabacasereport AT mooreassaf notonlyformelanomasubcutaneouspseudoprogressioninlungsquamouscellcarcinomatreatedwithnivolumabacasereport AT dudnikelizabeth notonlyformelanomasubcutaneouspseudoprogressioninlungsquamouscellcarcinomatreatedwithnivolumabacasereport AT pelednir notonlyformelanomasubcutaneouspseudoprogressioninlungsquamouscellcarcinomatreatedwithnivolumabacasereport |